|
WO2020253867A1
|
|
Small-molecule compound having a2a adenosine receptor antagonism
|
|
WO2020253870A1
|
|
6-hydrazinoadenosine compound having a2a adenosine receptor agonist activity
|
|
WO2020253866A1
|
|
Adenosine compound, pharmaceutically acceptable salt or stereoisomeride thereof, and use
|
|
WO2020253872A1
|
|
2-benzylidene hydrazinoadenosine compounds having a2a adenosine receptor agnostic activity
|
|
WO2020216350A1
|
|
Quinoline compounds and pharmaceutical compositions and uses thereof
|
|
WO2020216349A1
|
|
Enterovirus inhibitor
|
|
WO2020220846A1
|
|
Fusion protein capable of self-assembling into protein nanoparticles and application thereof
|
|
WO2020135569A1
|
|
Ethylenediamine compound and use thereof
|
|
WO2020057543A1
|
|
Aryl nitro-based linker, linker-containing antibody-drug conjugate, and use of linker
|
|
AU2019100932A4
|
|
Sustained-release nano-drug for targeting neurodegenerative disease
|
|
WO2019223642A1
|
|
Antiviral polypeptide, and pharmaceutical composition and application thereof
|
|
CN108210507A
|
|
A kind of pharmaceutical composition for preventing Alzheimer disease
|
|
WO2019136824A1
|
|
Mers-cov infection inhibiting polypeptide
|
|
CN108222561A
|
|
A kind of novel casualty decontamination shelter
|
|
CN108220200A
|
|
For treating micro- anaerobic bacteria of colitis and its application
|
|
EP3000807A1
|
|
Mercaptonicotinic acid compound and preparation method and use thereof
|
